Results 161 to 170 of about 125,678 (274)

Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Effective drug treatment of motor and non‐motor symptoms in Parkinson's disease (PD) often requires the administration of several anti‐Parkinson drugs in complex treatment regimens. The successful autonomous application of drugs places high demands on therapy adherence, which in turn relies on sufficient medication knowledge ...
Stephan Greten, Sarana Ulaganathan, Johannes Heck, Lan Ye, Matthias Höllerhage, Christoph Schrader, Corinna Ziemann, Olaf Krause, Florian Wegner, Martin Klietz   +9 more
wiley   +1 more source

Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia. [PDF]

Nat Commun, 2021
Gasca-Salas C, Fernández-Rodríguez B, Pineda-Pardo JA, Rodríguez-Rojas R, Obeso I, Hernández-Fernández F, Del Álamo M, Mata D, Guida P, Ordás-Bandera C, Montero-Roblas JI, Martínez-Fernández R, Foffani G, Rachmilevitch I, Obeso JA.   +14 more
europepmc   +1 more source

Predicting the Severity of Parkinson's Disease Dementia by Assessing the Neuropsychiatric Symptoms with an SVM Regression Model. [PDF]

Int J Environ Res Public Health, 2021
Byeon H.
europepmc   +1 more source

Patient‐Reported Communication Decline Following Deep Brain Stimulation in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Objective decline in communication abilities following Deep Brain Stimulation (DBS) in People with Parkinson's disease (PwP) is common; however, patient perspectives remain under‐investigated. Objectives This study examined subjective change in communicative efficacy using the Communicative Participation Item Bank (CPIB) in PwP ...
Stephanie M. Simone, Federico Rodriguez‐Porcel, Travis H. Turner   +2 more
wiley   +1 more source

Depression and Dementia in Parkinson’s Disease

Acta Clinica Croatica, 2015
Parkinson’s disease (PD) is a neurodegenerative disorder causing not only motor dysfunction but also cognitive, psychiatric, autonomic and sensory disturbances.
Osman Sinanović, Josip Hudić, Sanela Zukić, Almasa Kapidžić, Lejla Zonić, Mirjana Vidović   +5 more
doaj  

Transient receptor potential V1 modulates neuroinflammation in Parkinson's disease dementia: Molecular implications for electroacupuncture and rivastigmine. [PDF]

Iran J Basic Med Sci, 2021
Tsai ST, Wei TH, Yang YW, Lu MK, San S, Tsai CH, Lin YW.   +6 more
europepmc   +1 more source

Increased expression of pathological markers in Parkinson's disease dementia post-mortem brains compared to dementia with Lewy bodies. [PDF]

BMC Neurosci, 2022
Tu H, Zhang ZW, Qiu L, Lin Y, Jiang M, Chia SY, Wei Y, Ng ASL, Reynolds R, Tan EK, Zeng L.   +10 more
europepmc   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Comparing phenotypic features between Parkinson's disease dementia and dementia with Lewy bodies. [PDF]

J Neurol
Gunawardana CW, Burke PGR, Ignatavicius A, Matar E, Lewis SJG.   +4 more
europepmc   +1 more source

Neuroinflammation and protein pathology in Parkinson's disease dementia. [PDF]

Acta Neuropathol Commun, 2020
Kouli A, Camacho M, Allinson K, Williams-Gray CH.   +3 more
europepmc   +1 more source